Phase 4 N=250 Study of the Effectiveness of Administration of Meperidine on the Length of Active Phase of Labor in Women
Labor Pain
Primary: The Duration of Active Phase of Labour — 249; 304 minutes — p=0.029
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=37 Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide
Hiv
Primary: Percentage of Urine Samples Containing TFV in Concentrations Greater Than or Equal to 1000ng/mL From the 7-dose Cohort (1b). — 100; 80; 80; 80 percentage of urine samples
N/A N=1,493 A Trial Comparing Noninvasive Ventilation Strategies in Preterm Infants Following Extubation
Intubated Infants Were Intend to Extubation Using Noninvasive Ventilation Strategies
Primary: Duration of Invasive Mechanical Ventilation — 6.3; 7.8; 7.3 day
N/A N=22 Clinical Performance of a Silicone Hydrogel Contact Lens Following Six Nights of Extended Wear
Refractive Errors
Primary: Visual Acuity (VA) With Study Lenses, Collected by Eye — -0.04; -0.06; -0.06; -0.09 logMAR
N/A N=30 Oxygen Reserve Index (ORi) Validation of INVSENSOR00029
Healthy
Primary: Sensitivity for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values. — 93.63 percentage of true positives
Phase 2 N=40 Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
Non-Hodgkins Lymphoma · Multiple Myeloma · B-All
Primary: Best Response and Overall Response Rate — 33.3; 0; 16.7; 18.2 percentage of participants
Phase 3 N=52 Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis
Malignant Neoplasms of Male Genital Organs
Primary: Post-Operative Pain Medication Usage in Post Anesthesia Care Unit (PACU) — 13.0208; 15.1786 mg
Phase 3 N=205 Topical Ibuprofen for Delayed Onset Mulscle Soreness
Pain
Primary: Change From Baseline in the Time-Weighted Sum of Muscle Soreness With Movement Over 0-24 Hours Post-Dose 1 (MSM 0-24 ) — 22.2; 17.8; 29.7 units on a scale — p=0.200
Phase 3 N=477 Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
Age-related Macular Degeneration (AMD)
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 8 Weeks — 5.1; 5.6; 5.4 letters
N/A N=27 "Ounce-equivalents" in the Protein Foods Group: Benefits of Quality
Protein Metabolism
Primary: Net Protein Synthesis Rate — 8.65; 1.97; 5.69 grams — p=<0.05
Phase 1 N=260 Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Metastatic Cancer · Solid Tumors · Colorectal Cancer (CRC)
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 7; 7; 81; 7 Participants
N/A N=11,834 The Impact of Vaccination on Severity of Illness in COVID-19
Covid19
Primary: Number of Participants With Emergency Center (EC) Encounters and/or Hospitalizations With Positive COVID-19 Test — 10880; 825; 129 Participants
N/A N=32 Elderly Demented Patients: Aromatherapy Complementary to Psychopharmacotherapy Psychological Disorders and BPSD Behavior
BPSD (Behavioral and Psycological Symptoms of Dementia)
Primary: Role of Essential Oil Therapy in Environmental Diffusion as a Complement of Psychotropic Drugs in the Management of Psychological and Behavioral Disorders (BPSD)…
Phase 2 N=29 Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites
Bacterial Infection
Primary: Number of Participants With Adverse Events — 5; 4; 1; 6 participants
N/A N=143 Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery
Postpartum Hemorrhage
Primary: Change in Hemoglobin — 1.08; 1.20 mg/dl